Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2018-09-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
第七届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's seventh board of directors' ninth meeting. It details the meeting's convening, voting results on specific transactions involving equity transfers, and mentions that these matters will be submitted to the shareholders' meeting for approval. The document includes references to compliance with legal and regulatory requirements and mentions related announcements published elsewhere. The document length is short (1282 characters), and it primarily serves as a public notice of board decisions rather than a full report or detailed financial disclosure. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. It is not an annual report, audit report, or earnings release, nor is it a proxy solicitation or voting result declaration. Therefore, the appropriate classification is MANG with high confidence.
2018-09-20 Chinese
拟出让南京金陵大药房有限责任公司30%股权项目资产评估说明
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for a 30% equity stake in a company (南京金陵大药房有限责任公司). It includes extensive sections on asset evaluation scope, asset verification, valuation methods (income and market approaches), financial and operational analysis, and industry and regulatory environment analysis. The document is lengthy (15,000 characters) and contains substantive financial data, asset details, and valuation conclusions. It is not a brief announcement or a certification letter but a full asset appraisal report. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone asset valuation report with audit references and detailed financial analysis, but it is not a full annual or interim report. Therefore, the appropriate classification is AR with high confidence.
2018-09-20 Chinese
南京金陵大药房有限责任公司2018年8月31日净资产审计专项报告
Audit Report / Information Classification · 100% confidence The document is titled as a "净资产审计专项报告" which translates to a "Net Asset Audit Special Report". It is issued by an accounting firm (天衡会计师事务所) and contains detailed audit opinions, responsibilities of management and auditors, and includes comprehensive financial statements such as balance sheets, income statements, and cash flow statements for periods ending 2017 and 2018. The document is about auditing the financial statements of 南京金陵大药房有限责任公司 and is clearly an audit report on the net assets as of August 31, 2018. It is not an annual report or interim report but a standalone audit report focusing on the net asset audit. The length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is Audit Report / Information (AR). Q3 2018
2018-09-20 Chinese
拟出让南京华东医药有限责任公司51%股权项目资产评估说明
Audit Report / Information Classification · 95% confidence The document is an extensive asset evaluation report related to the proposed sale of a 51% equity stake in a company. It includes detailed asset appraisal, valuation methods, asset verification, and audit references. The content is technical and financial, focusing on asset valuation rather than a general annual report or earnings release. It is not a brief announcement or a certification letter but a comprehensive asset appraisal document. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to asset valuation and financial verification, excluding full annual reports. The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2018-09-20 Chinese
南京华东医药有限责任公司2018年08月31日净资产审计专项报告
Audit Report / Information Classification · 100% confidence The document is titled as a "净资产审计专项报告" (Net Asset Audit Special Report) dated August 31, 2018, issued by an accounting firm (天衡会计师事务所). It contains detailed audit opinions, responsibilities of management and auditors, and includes consolidated financial statements such as balance sheets and profit statements for the period ending August 31, 2018. The content is a standalone audit report focusing on the audit of net assets and financial statements, not a full annual report or interim report. It is not an announcement or certification but a full audit report with substantive financial data and auditor opinions. Therefore, it fits the category of Audit Report / Information (AR).
2018-09-20 Chinese
独立董事关于公司第七届董事会第九次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting resolutions regarding the transfer of company equity stakes. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on the board meeting's approval process and fairness of related party transactions. It does not contain financial statements or detailed financial results, nor is it a general announcement or a report publication notice. The document is clearly related to board/management information, specifically the independent directors' opinions on board resolutions and related matters.
2018-09-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.